Applications of Fmoc-(R)-3-Amino-3-(4-Bromo-Phenyl)-Propionic Acid in Industrial Manufacturing

Fmoc-(R)-3-Amino-3-(4-Bromo-Phenyl)-Propionic Acid serves as a key chiral intermediate in industrial peptide synthesis and specialized organic chemistry. As the original producer, we apply validated methods to supply this compound for demanding synthesis routes across regulated industrial sectors. Below, we present precise, real-world downstream applications where this intermediate adds direct manufacturing value, with documented compliance, established dosage guidance, process context, and typical finished products.

1. Pharmaceutical Peptide Active Pharmaceutical Ingredient (API) Synthesis

This compound offers a critical enantiopure building block for the industrial synthesis of complex peptides, supporting the development of pharmaceutical APIs targeting therapeutic indications that require non-canonical amino acid incorporation. Manufacturing protocols use it in solid-phase peptide synthesis (SPPS) to introduce functionalized β-amino acid motifs, often in late-stage platform manufacturing for oncology and metabolic disorder drugs.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• cGMP (21 CFR Parts 210/211 US FDA)
• EP/USP/JP monographs addressing peptide APIs
• ISO 9001:2015 for quality management in intermediate production

Typical usage ratio

• Used at 0.25–2.5 mmol per elongation cycle in SPPS, adjusted to match target sequence length and loading on resin

Downstream process integration

• Fmoc-(R)-3-Amino-3-(4-Bromo-Phenyl)-Propionic Acid enters the automated peptide synthesizer after resin activation, coupled as one of the programmed amino acid additions prior to Fmoc deprotection and elongation cycles

Final product types

• Peptide-based Active Pharmaceutical Ingredients (APIs)
• Anticancer peptide drugs with modified side chains
• Metabolic disease peptide therapies

2. Custom Peptide Reagents for Diagnostic Kit Production

Diagnostic kit manufacturers require highly pure, sequence-defined peptides containing chiral β-amino acids to enhance specificity and accuracy in immunoassays. Our material supports custom peptide synthesis for MRM standards, peptide calibrators, and in vitro diagnostic reagents. Compliance relies on traceable batch production and validated impurity control, as demanded by quality-focused downstream users in clinical and laboratory assay supply.

Industry compliance standards

• ISO 13485:2016 (Medical device and IVD quality management system)
• IVDR (EU 2017/746 for in vitro diagnostic medical devices)
• ISO 17025 for reference standard manufacturers
• Certificate of Analysis supporting traceability for research-use-only (RUO) grade reagents

Typical usage ratio

• Blended at 0.1–2% of total peptide content in custom reagent batches, depending on target peptide structure and function in end assay

Downstream process integration

• Added during automated or manual peptide chain assembly using Fmoc chemistry, then purified by preparative HPLC prior to lyophilization in diagnostic mixing lines

Final product types

• Peptide calibrators for mass spectrometry kits
• Peptide antigens for enzyme immunoassay kits
• Reference standards for biomedical diagnostics

3. Chiral Ligand Precursor for Asymmetric Catalysis Manufacturing

This amino acid analog is a favored chiral precursor in specialty ligand synthesis for asymmetric catalysis processes. It allows catalyst developers to introduce precise stereochemical control elements critical for pharmaceutical and fine chemical production. Manufacturing partners scale up its use within ligand functionalization toolkits, following established catalyst technology protocols and real process validation steps.

Industry compliance standards

• ISO 9001:2015 for chemical synthesis and ligand production QA/QC
• REACH (EC No 1907/2006) registration for downstream users in the EU
• Food Contact Materials (Regulation EC 1935/2004) if used in food/intermediate sector catalysis
• Custom MSDS/CoA documentation for non-pharma catalyst manufacture

Typical usage ratio

• Added at 1–8 mol% relative to metal catalyst center, depending on stereochemical control requirements and ligand loading protocols in target catalytic process

Downstream process integration

• Serves as a starting chiral subunit in ligand synthesis reactors, functionalized through amide coupling or other organic transformations prior to final catalyst assembly

Final product types

• Chiral phosphine or diamine ligands for asymmetric hydrogenation
• Catalytic intermediates for API and agrochemical production
• Ligand-controlled synthesis kits for industrial R&D

4. Specialty Chemical for High-Value Fine Chemical Synthesis

In the fine chemicals sector, advanced β-amino acid derivatives enable the creation of functionalized organic intermediates with defined halogen patterns. Fmoc-(R)-3-Amino-3-(4-Bromo-Phenyl)-Propionic Acid delivers site-specific bromination and stereochemistry, making it suitable for downstream brominated building block production in specialty polymer, agrochemical, and advanced material manufacturing flows. Process engineers optimize its use to maximize yield and stereopurity in challenging multi-step organic syntheses.

Industry compliance standards

• ISO 9001:2015 for chemical intermediates production QA
• REACH Annex VII, VIII or IX registration, based on usage volume in the EU
• Responsible Care chemical management frameworks
• HSE process safety requirements for halogenated intermediates

Typical usage ratio

• Employed at 0.5–5 mol% in organic synthesis, depending on transformation target, with usage optimized through reaction monitoring and downstream purification constraints

Downstream process integration

• Introduced as a key reactant for amide coupling, protection-deprotection cycles, or aryl bromination steps in multi-stage laboratory or pilot scale synthesis

Final product types

• Brominated fine chemicals for electronic materials
• Chiral auxiliaries for crop protection agents
• High-value specialty intermediates for advanced synthesis supply chains